Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Re Antares royalties, she didn't break it down overtly but near the end of question time the CFO pointed out the effect of Antares bolted on to the core income stream. Wasn't much, maybe +5% if I recall correctly.
I doubt that we'll see any upgrades after this call. Two reasons:
a.) There were some optimistic comments about new partners but the CFO really deflated the conversation in response to a question about plans for growth and all she could point to was the share buybacks. (Sigh....)
b.) The primary analysts were absent, probably on vacation at their beach houses, leaving the matters to scrubs and interns. They can ask a question or two but they aren't allowed to press any buttons. LOL!
Agreed about risk/reward, though, so staying the course.
-Fritz